Parkinson's Disease - Drug Pipeline Landscape, 2023
Parkinson's Disease (PD) simply called as Parkinson's, is a progressive neuro-degenerative disorder which mainly affects the motor systems due to the depletion in dopamine. The motor symptoms result from the death of cells in the substantia nigra leading to dopamine deficit. The cause of cell death involves the build-up of misfolded proteins into Lewy bodies in the neurons. Collectively known as Parkinsonian Syndrome.
The main cause of PD is not known. The environmental triggers, genetics are the associated factors in the cause of PD. Pesticides, herbicides and proximity to industrial plants, drugs are linked to the cause. The oxidation and generation of free radicals may be the cause of damage of thalamic nuclei.
The symptoms will slowly emerge. Early symptoms are tremors I hands, arms, legs and face, rigidity, slowness in the movement, difficulty walking, impaired balance and coordination. Other symptoms associated with cognitive and behavioural problems including depression, anxiety and apathy.
Parkinson's disease is diagnosed based on medical history and also based on signs and symptoms. Single-photon emission computerized tomography (SPECT) scan and dopamine transporter (DAT) scan helps in determining the disease. Imaging tests including MRI, CT and PET scans also helps in diagnosing the disease.
The main goal is to reduce PD symptoms. Treatment includes medications, surgery and physical treatment. The drugs that are helps in treating motor symptoms are dopa decarboxylase inhibitors, COMT inhibitor, dopamine agonists and MAO-B inhibitors. Late-stage PD requires psychiatric treatment. In final stage palliative care should be provided to improve person's quality of life.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Parkinson’s Disease treatment such as ABBV-951, SPN-830, Buntanetap, E2027, and others. Key players involved in the development of therapies to treat Parkinson’s Disease are AbbVie, BenevolentAI, Novartis, Sumitomo Pharma and others. Two drugs are under late-stage Pre-registration, 30+ Phase III clinical trials and 10+ drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.In Oct 2022, Supernus Pharmaceuticals Inc announced that the U.S. FDA has issued a complete Response Letter (CRL) for SPN-830 New Drug Application (NDA).
Global Insight Service's, Parkinson's Disease - Drug Pipeline Landscape, 2023 report provides an overview of the Parkinson's Disease pipeline drugs. This report covers detailed insights on Parkinson's Disease drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Parkinson's Disease pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook